Technology | October 12, 2009

GE Launches New 16-Slice SPECT/CT in Europe

GE Launches New 16-Slice SPECT/CT in Europe

Discovery NM/CT 670

October 11, 2009 – GE Healthcare announced the European launch of Discovery NM/CT 670, a hybrid imaging platform designed to improve workflow, dose management, and overall image quality, during the EANM'09 Annual Congress of the European Association of Nuclear Medicine, held Oct. 10-14 in Barcelona, Spain.

The system combines GE Healthcare’s BrightSpeed Elite 16-slice CT, a newly designed SPECT gantry for greater positional flexibility, and the latest advancements in Nuclear Medicine detectors.

The Discovery NM/CT 670 is designed enable physicians to perform advanced hybrid and standalone CT procedures. The Discovery NM/CT 670 platform incorporates flexible and proven workflow technology advancements from 10 years of Infinia Hawkeye innovations and installations with a modular gantry, designed to embrace tomorrow’s technology today. The BrightSpeed Elite, providing proven multi-slice CT performance, completes the academic system.

“With the combination of advanced CT and SPECT technology available on the Discovery NM/CT 670, we will be able to optimize both our SPECT and standalone CT protocols,” said professor Ora Israel from Rambam Medical Center, Israel.

The Discovery NM/CT 670 also has the capability to shorten acquisition times, improve dose management, and enable more convenient patient scheduling in comparison to separate, conventional SPECT and CT exams.

Keeping the patient in mind, the system is said to able to reduce scan time dramatically. Bone imaging protocols, including planar whole body, 3D SPECT and CT attenuation correction/localization, are amongst the most frequently performed nuclear medicine procedures. With conventional nuclear hybrid imaging, a traditional bone imaging protocol can take up to 55 minutes. With the Discovery NM/CT 670, the time is reduced to as little as 25 minutes. This reduction in time can be less painful, and possibly reduce patient movement due to the pain or uncomfortable positioning, minimizing artifacts in the scan. A shorter, more comfortable scan also has the potential to improve image quality, allowing clinicians to be more confident in their diagnosis.

The Discovery NM/CT 670 is 510(k) pending at FDA. It is not available for sale in the United States.

For more information: www.gehealthcare.com

Related Content

Videos | SPECT-CT | December 12, 2018
This is a walk around of the new Spectrum Dynamics Veriton SPECT-CT nuclear imaging system introduced at the 2018 ...
Spectrum Dynamics Sues GE for Theft, Misappropriation of Trade Secrets and Unfair Competition
News | SPECT Imaging | December 06, 2018
Single-photon emission computed tomography (SPECT) cardiac imaging company Spectrum Dynamics filed a lawsuit Dec. 6,...
A PET/CT head and neck cancer scan.

A PET/CT head and neck cancer scan.

Feature | Nuclear Imaging | November 05, 2018 | By Sabyasachi Ghosh
“Experimental validation implemented in real-life situations and not theoretical claims exaggerating small advantages
Siemens Healthineers Announces FDA Clearance of syngo.via VB30 Molecular Imaging Software
Technology | Nuclear Imaging | July 16, 2018
At the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), June 23-26 in Philadelphia...
Cardiac MRI being performed at the DeBakey Heart Hospital.

Cardiac MRI being performed at the DeBakey Heart Hospital.

Feature | Cardiac Imaging | May 03, 2018 | By Jeff Zagoudis
Magnetic resonance imaging (MRI) for cardiac assessment provides a radiation-free alternative to other commonly used...
The Chalk River nuclear reactor license has been renewed, but will be decommissioned by 2028.

The Chalk River nuclear isotope reactor license has been renewed, but will be decommissioned by 2028. The reactor supplies about 50 percent of the world's supply of Tc99m.

Feature | Nuclear Imaging | April 02, 2018 | Dave Fornell
April 2, 2018 – The Canadian Nuclear Safety Commission (CNSC) announced March 29 that it renewed Canadian Nuclear Lab
A Tc99m SPECT cardiac exam showing myocardial perfusion in the heart.

Technetium-99m is primarily used for the detection of cancer and to assess perfusion defects in the heart caused by heart attacks or other conditions.

Feature | Radiopharmaceuticals and Tracers | February 08, 2018 | Dave Fornell
February 8, 2018 — The U.S.
Videos | Nuclear Imaging | August 24, 2017
Prem Soman, M.D., director of nuclear cardiology at the Heart and Vascular Institute, University of Pittsburgh, and p
GE Healthcare SPECT/CT and PET/CT Systems Enhance Personalized Patient Care
News | Nuclear Imaging | June 10, 2017
GE Healthcare showcased positron emission tomography (PET) and single photon emission computed tomography/computed...
advanced visualization
News | Molecular Imaging | June 09, 2017
The Food and Drug Administration (FDA) has cleared syngo.via VB20 for Molecular Imaging (MI) from Siemens Healthineers...